Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Regulators Ramp Up Safety Monitoring Efforts For Biologicals

This article was originally published in SRA

Executive Summary

It is well known that biological medicinal products are different from chemically synthesized medicines and that these differences are recognized in terms of the data required to support their evaluation. Regulatory authorities are now ramping up efforts to produce dedicated programs and guidance to support the pharmacovigilance of biologicals, reports Vibha Sharma.

You may also be interested in...

Need For Consensus On Pharmacovigilance For Drugs In Pregnancy Delays New EMA Guideline

A new draft guideline from the European Medicines Agency on pharmacovigilance requirements relating to medicines taken during pregnancy and breastfeeding has been delayed and will now be issued for stakeholder consultation by the end of 2017.

Pharma Worried Over Implementation of EMA's Traceability Requirements For Biologicals

EU pharmaceutical companies believe that batch traceability and product identification requirements in the European Medicines Agency's recently-finalized guideline on pharmacovigilance of biological medicines does not take into account the realities and practicalities of marketing such products.

UK To Use COVID-19 Learnings To Speed Up Review Of Other Trials

A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts